“Pancreatic cancer,” Young-Joon said. “Analyze pancreatic cancer. You can do it now, right?”1

Rosaline’s level was higher now and she had more fitness; she had grown enough for her to be able to show cancer as an option.0

There were two reasons why Young-Joon chose pancreatic cancer as his target. First of all, it was difficult to start the follow-up research for stem cells right now as all the stem cells experts in the company had to focus on the clinical trial for the Alzheimer’s cure. Second, A-Bio would already be created by the time this project was on track, which meant that this was the first research he would do as the CEO of A-Bio and not an A-Gen scientist. Put differently, it meant that A-Bio was entering the anticancer drug market.0

It was true that the public still focused on stem cells when thinking of A-Bio. Everyone thought that it was a regenerative medicine company. But A-Bio couldn’t just be that; this company had to be the frontier that dominated all areas of the pharmaceutical industry. That was why they had probiotics, a healthcare product. Of course, cancer, the largest disease that threatened humanity, could not be an exception. This research was going to be one that showed what A-Bio was.0

Then, why did Young-Joon choose pancreatic cancer as his target when pancreatic cancer only accounted for two percent of all cancer patients? It was because it was...4